Therapeutic nuclear medicines are a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intending for the treatment of cancer, metastatic bone pain and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumor and reducing pain.

Market Analysis and Insights: Global Nuclear Drug for Therapeutic Market
The global Nuclear Drug for Therapeutic market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nuclear Drug for Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nuclear Drug for Therapeutic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nuclear Drug for Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nuclear Drug for Therapeutic market.

Global Nuclear Drug for Therapeutic Scope and Market Size
Nuclear Drug for Therapeutic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nuclear Drug for Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Radium-223
Lutetium-177
Iodine-131
Other

Segment by Application
Thyroid
Bone Metastasis
Lymphoma
Other

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bayer
Novartis
China Isotope & Radiation
Dongcheng
Q BioMed
Curium Pharmaceuticals
Jubilant DraxImage
Lantheus
Spectrum Pharmaceuticals
Progenics Pharmaceuticals
International Isotopes